Consensus Document on the Overlap Phenotype COPD-Asthma in COPD;Documento de consenso sobre el fenotipo mixto EPOC-asma en la EPOC

Archivos de Bronconeumologia

Volumn 48, Issue 9, 2012, Pages 331-337

  Soler Cataluña, Juan José ^a   Cosío, Borja ^b   Izquierdo, José Luis ^c   López Campos, José Luis ^d   Marín, José M ^e   Agüero, Ramón ^f   Baloira, Adolfo ^g   Carrizo, Santiago ^e   Esteban, Cristóbal ^h   Galdiz, Juan B ⁱ   González, M Cruz ^j   Miravitlles, Marc ^k   Monsó, Eduard ^l   Montemayor, Teodoro ^m   Morera, Josep ⁿ   Ortega, Francisco ^d   Peces Barba, Germán ^o   Puente, Luis ^p   Rodríguez, José Miguel ^p   Sala, Ernest ^b   Sauleda, Jaume ^b   Soriano, Joan B ^q   Viejo, José Luis ^r   more..

^a HOSPITAL GENERAL DE REQUENA   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^c HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g HOSPITAL MONTECELO   (Spain)

^h HOSPITAL DE GALDAKAO   (Spain)

ⁱ HOSPITAL DE CRUCES   (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^k HOSPITAL CLÍNIC   (Spain)

^l HOSPITAL DE SABADELL   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

ⁿ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^o HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^p HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^q Fundacion Caubet CIMERA   (Spain)

^r HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

more..

Author keywords

Asthma; Chronic obstructive pulmonary disease; Diagnosis; Phenotype; Respiratory disease; Treatment

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E;

ARTICLE; ASTHMA; ATOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSENSUS DEVELOPMENT; DISEASE CLASSIFICATION; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LUNG FUNCTION TEST; MEDICAL HISTORY; OVERLAP PHENOTYPE CHRONIC OBSTRUCTIVE LUNG DISEASE ASTHMA; PHENOTYPE; PRACTICE GUIDELINE; SPUTUM ANALYSIS;

EID: 84864863776     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2012.06.017     Document Type: Article

References (33)

1. Peces-Barba G., Barberà J.A., Agustí A., Casanova C., Casas A., Izquierdo J.L., et al. Guía Clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol 2008, 44:271-281.
2. GEMA 2009 Guía Española para el Manejo del Asma 2009, Luzan, Madrid.
3. Gibson P.G., Simpson J.L. The overlap syndrome of asthma and COPD: what are its features and how important is it?. Thorax 2009, 64:728-735.
4. Tashkin D.P., Celli B., Decramer M., Liu D., Burkhart D., Cassino C., et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008, 31:742-750.
5. Siva R., Green R.H., Brightling C.E., Shelley M., Hargadon B., Mckenna W., et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007, 29:906-913.
6. Miravitlles M. Tratamiento individualizado de la EPOC: una propuesta de cambio. Arch Bronconeumol 2009, 45(Suppl 5):27-34.
7. Miravitlles M., Calle M., Soler-Cataluña J.J. Fenotipos clínicos de la EPOC. Identificación, definición e implicaciones para las guías de tratamiento. Arch Bronconeumol 2011, 10.1016/j.arbres.2011.10.007.
8. Herland K., Akselsen J.P., Skjønsberg O.H., Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?. Respiratory Medicine 2005, 99:11-19.
9. Petty T.L. The history of COPD. Int J Chron Obstruct Pulmon Dis 2006, 1:3-14.
10. UNICEF. Visualisation in participatory programmes. A manual for facilitators and trainers involved in participatory group events. Bangladesh; 1993 [consultado 2011]. Disponible en: http://portals.wi.wur.nl/files/docs/ppme/VIPP_Unicef.pdf.
11. Kaner S., Lind L., Toldi C. A Facilitator's Guide to Participatory Decision Making 2007, John Wiley & Sons/Jossey-Bass, USA.
12. Burrows B., Bloom J.W., Traver G.A., Cline M.G. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987, 317:1309-1314.
13. Orie N.G.M., Sluiter H.J., De Vries K., Tammeling G.J., Witkop J. The host factor in bronchitis. Bronchitis 1961, 43-59. Royal Van Gorcum, Assen, The Netherlands. N.G.M. Orie, H.J. Sluiter (Eds.).
14. Tinkelman D.G., Price D.B., Nordyke R.J., Halbert R.J., Isonaka S., Nonikov D., et al. Symptom-based questionnaire for differentiating COPD and asthma. Respiration 2006, 73:296-305.
15. Leigh R., Pizzichini M.M., Morris M.M., Maltais F., Hargreave F.E., Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006, 27:964-971.
16. Williamson P.A., Menzies D., Clearie K.L., Vaidyanathan S., Lipworth B.J. Dose-response for inhaled fluticasone on airway and systemic inflammation in COPD. Eur Respir J 2011, 37:206-209.
17. Welte T., Miravitlles M., Hernandez P., Eriksson G., Peterson S., Polanowski T., et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:741-750.
18. Van der Valk P., Monninkhof E., van der Palen J., Zielhuis G., van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002, 166:1358-1363.
19. Wouters E.F., Postma D.S., Fokkens B., Hop W.C., Prins J., Kuipers A.F., et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005, 60:480-487. COSMIC (COPD, Seretide: a Multi-Center Intervention, Characterization) Study Group.
20. Cosío B.G., Fiorentino F., Scrimini S. EPOC y asma. Arch Bronconeumol 2010, 46(Suppl 8):2-7.
21. Brindicci C., Ito K., Resta O., Pride N.B., Barnes P.J., Kharitonov S.A. Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J 2005, 26:52-59.
22. Rutgers S.R., van der Mark T.W., Coers W., Moshage H., Timen W., Kaufmann H.F., et al. Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease. Thorax 1999, 54:566-580.
23. Papi A., Romagnoli M., Baraldo S., Braccioni F., Guzzinati I., Saetta M., et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 162:1773-1777.
24. Lehtimäki L., Kankaanranta H., Saarelainen S., Annila I., Aine T., Nieminen R., et al. Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD. Eur Respir J 2010, 35:72-78.
25. Singh S., Amin A.V., Loke Y.K. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009, 169:219-229.
26. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., Dorinsky P.M. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006, 129:15-26. SMART Study Group.
27. Barnes P.J. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thor Soc 2005, 2:334-339.
28. Han M.K., Agustí A., Calverley P.M., Celli B.R., Criner G., Curtis J.L., et al. Chronic obstructive pulmonary disease phenotypes. The future of COPD. Am J Respir Crit Care Med 2010, 182:598-604.
29. Hardin M., Silverman E.K., Barr R.G., Hansel N.N., Schroeder J.D., Make B.J., et al. The clinical features of the overlap between COPD and asthma. Respir Res 2011, 12:127. 10.1186/1465-9921-12-127.
30. Hospers J.J., Postma D.S., Rijcken B., Weiss S.T., Schouten J.P. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000, 356:1313-1317.
31. Vestbo J., Edwards L.D., Scanlon P.D., Yates J.C., Agusti A., Bakke P., et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011, 365:1184-1192.
32. Hacia un nuevo enfoque en el tratamiento de la EPOC. Guía Española de la EPOC (GESEPOC). Arch Bronconeumol 2011, 47:379-381. Grupo de trabajo de GESEPOC.
33. Nadeem N.J., Taylor S.J., Eldridge S.M. Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology. Respir Res 2011, 12:107.